Cargando…

The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)

Detalles Bibliográficos
Autores principales:	Leinonen, Mika, Hallén, Bengt, Olivecrona, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184312/ http://dx.doi.org/10.1186/1546-0096-12-S1-P76

Ejemplares similares

PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret(®)) in patients with severe CAPS
por: Wikén, M, et al.
Publicado: (2013)

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
por: Kullenberg, Torbjörn, et al.
Publicado: (2016)

PW02-039 - Long-term anakinra treatment in CAPS: a metaanalys
por: Leinonen, M, et al.
Publicado: (2013)

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
por: Kaiser, Christina, et al.
Publicado: (2011)

Effect of the IL-1 Receptor Antagonist Kineret(®) on Disease Phenotype in mdx Mice
por: Benny Klimek, Margaret E., et al.
Publicado: (2016)

Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra
por: Terrada, Celine, et al.
Publicado: (2011)

Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study
por: Gibbs, A, et al.
Publicado: (2005)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes
por: Bachove, Inessa, et al.
Publicado: (2014)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
por: Church, Leigh D, et al.
Publicado: (2008)

Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret(®)) in systemic juvenile idiopathic arthritis
por: Livermore, P, et al.
Publicado: (2008)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Cryopyrin associated periodic syndromes (CAPS): immunological characterization of knock-in mouse model to exploit novel approaches for the modulation of the NLRP3 inflammasome.
por: Bertoni, A, et al.
Publicado: (2015)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Quartier, Pierre
Publicado: (2011)

Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome
por: Karasawa, Tadayoshi, et al.
Publicado: (2022)

Cryopyrin-associated Periodic Syndrome in a Family with NLRP3 A441V Mutation
por: SHIRAISHI, Ken, et al.
Publicado: (2022)

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

A Rare Case of Cryopyrin-associated Periodic Syndrome in an Elderly Woman with NLRP3 and MEFV Mutations
por: Nakamichi, Seiko, et al.
Publicado: (2018)

Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome
por: Stackowicz, Julien, et al.
Publicado: (2021)

Computational Modeling of NLRP3 Identifies Enhanced ATP Binding and Multimerization in Cryopyrin-Associated Periodic Syndromes
por: Samson, Jenny Mae, et al.
Publicado: (2020)

CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction
por: Ito, Sayaka, et al.
Publicado: (2014)

Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
por: Salugina, SO, et al.
Publicado: (2011)

PReS-FINAL-2241: Cases of cryopyrin-associated periodic syndromes (CAPS) in one single rheumatologic center of Russia
por: Salugina, SO, et al.
Publicado: (2013)

Late onset of the cryopyrin-associated periodic syndrome (CAPS) associated with low level of somatic mosaicism in six patients
por: Rowczenio, D, et al.
Publicado: (2015)

The RaDiCEA Project: cost of illness (COI) analysis applied to Cryopyrin Associated Periodic Syndromes (CAPS)
por: Della Casa Alberighi, O, et al.
Publicado: (2015)

Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System
por: Keddie, Stephen, et al.
Publicado: (2018)

The role of somatic NLRP3 mosaicism and new gene discovery in mutation negative cryopyrin-associated periodic syndrome patients
por: Gomes, Sonia Melo, et al.
Publicado: (2014)

Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism—UK Single Center Experience
por: Rowczenio, Dorota M., et al.
Publicado: (2017)

NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies
por: Moltrasio, Chiara, et al.
Publicado: (2022)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Description of a case of late-onset cryopyrin-associated periodic syndrome due to low-level somatic NLRP3 mosaicism
por: Mensa-Vilaro, A, et al.
Publicado: (2015)

Identification of a New Variant in NLRP3 Gene by Whole Exome Sequencing in a Patient with Cryopyrin-Associated Periodic Syndrome
por: Vahedi, Mahdieh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_un1a4v2cvq1dftkgq252nr23do